Enables chondroitin sulfate proteoglycan binding activity; heparan sulfate proteoglycan binding activity; and syndecan binding activity. Involved in nervous system development; regulation of axon extension involved in axon guidance; and signal clustering. Located in membrane. Orthologous to human SEMA5A (semaphorin 5A); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-sulfonyldiphenol; 6-propyl-2-thiouracil.
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SEMA5A mRNA and [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SEMA5A gene
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SEMA5A mRNA more ...
[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of SEMA5A mRNA and [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of SEMA5A gene
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SEMA5A mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA5A mRNA
sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A
Sema5a_predicted
sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A (predicted)
sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A (predicted)